Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus K 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus K 8.
K-TAB vs K+8
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Hypokalemia prevention and treatmentHypokalemia due to diuretic therapyDigitalis intoxication with hypokalemiaFamilial periodic paralysis (hypokalemic form)
Treatment of hypokalemiaPrevention of hypokalemia in patients at risk (e.g., diuretic therapy)Digitalis intoxication
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Not metabolized; renally excreted.
Not metabolized; primarily excreted unchanged by the kidneys via distal tubular secretion.
Renal (90% unchanged), fecal (10% as metabolites)
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
80-90% bound to albumin and alpha1-acid glycoprotein
<10% bound; primarily to albumin. Binding is negligible.
1-2 L/kg, indicating extensive tissue distribution
0.3-0.4 L/kg (adults); Vd decreases in neonates and increases in pregnancy.
Oral: 92-100%
Oral immediate-release: 85-95%; extended-release: 80-90% (dependent on formulation). IV: 100%.
For GFR <30 mL/min/1.73 m²: reduce dose by 50% or use alternative; monitor serum potassium closely. Avoid if GFR <10 mL/min/1.73 m² unless on dialysis.
GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce dose by 25-50%; GFR <30 mL/min: avoid use or reduce dose by 50-75% with close monitoring.
No specific Child-Pugh adjustment. Use with caution in severe hepatic impairment due to risk of hyperkalemia from associated renal dysfunction.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose by 25%; Child-Pugh C: avoid use or reduce dose by 50% with monitoring.
Weight-based: 1-2 mEq/kg/day orally in divided doses, not to exceed 20 mEq per dose; adjust based on serum potassium and renal function.
0.5-1 mEq/kg intravenously per dose, not to exceed 1 mEq/kg/hour; or 1-3 mEq/kg/day orally divided 2-3 times daily.
Initiate at lower end of dosing range (e.g., 20 mEq/day) due to age-related decline in renal function; monitor potassium and renal function regularly.
Initiate at low end of dosing range (20-40 mEq/day) due to age-related decline in renal function; monitor serum potassium and renal function closely.
No FDA black box warning.
Potassium chloride injection concentrate must be diluted before use; direct injection can cause fatal hyperkalemia.
["Hyperkalemia risk, especially in renal impairment","Use with potassium-sparing diuretics increases hyperkalemia risk","Gastrointestinal lesions (ulceration, stricture) with wax-matrix tablets","Sudden cessation of high-dose potassium supplements may cause complications"]
Monitor serum potassium levels; caution in renal impairment, cardiac disease, acidosis; risk of hyperkalemia; avoid rapid intravenous infusion; use with caution in patients receiving potassium-sparing diuretics.
["Hyperkalemia","Severe renal impairment (eGFR <30 mL/min)","Addison's disease","Untreated Addison's disease","Concomitant potassium-sparing diuretics","Adrenal insufficiency","Acidosis (metabolic or respiratory)","Chronic renal failure","Acute dehydration","Extensive tissue breakdown (e.g., severe burns)"]
Hyperkalemia; severe renal impairment with oliguria or anuria; untreated Addison's disease; acute dehydration; extensive tissue breakdown (e.g., burns); concurrent use of potassium-sparing diuretics.
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, tomatoes) unless directed by your doctor. Do not use potassium-containing salt substitutes. Take with food to reduce gastric upset.
Avoid high-potassium foods (bananas, oranges, potatoes, spinach, avocados, tomatoes) if at risk of hyperkalemia. Limit intake of salt substitutes containing potassium chloride. Grapefruit juice may increase serum potassium; avoid excessive consumption.
K-TAB (potassium chloride) is FDA pregnancy category C. No fetal risks demonstrated at standard doses; hyperkalemia may cause fetal arrhythmia. First trimester: no known teratogenicity. Second/third trimesters: excess potassium can cross placenta, potentially causing fetal cardiac effects if maternal levels elevated.
Potassium supplementation (K+8) is not teratogenic. Normal maternal potassium levels are essential for fetal development. Hypokalemia or hyperkalemia may pose risks. First trimester: No evidence of teratogenicity. Second/third trimester: Monitor for electrolyte imbalance; hyperkalemia can cause fetal arrhythmias.
Potassium is normal constituent of breast milk. Supplementation unlikely to affect infant. M/P ratio approximately 1.1. Use with caution only if clearly needed, monitor infant for hyperkalemia signs.
Potassium is a normal component of breast milk. Supplementation in physiological doses does not pose risk to infant. M/P ratio: ~0.4-0.5 (similar to serum). No contraindication with breastfeeding.
No specific dose adjustment required for pregnancy; titrate based on serum potassium and clinical response. Renal clearance increases in pregnancy, may require higher doses for hypokalemia; avoid overcorrection.
Dose adjustment not typically required in pregnancy due to pharmacokinetic changes. However, increased plasma volume increases potassium requirements; monitor for hypokalemia. Start at lower end of dosing range and adjust based on serum potassium levels.
Category C
Category C
K-TAB is an extended-release potassium chloride tablet. Do not crush or chew; ensure patients can swallow whole. Monitor serum potassium levels regularly, especially in renal impairment or with concurrent ACE inhibitors/ARBs. Slow intravenous administration is critical if IV route used; never give IV push. Hyperkalemia risk is highest with rapid infusion or in renal failure.
Administer slowly IV to avoid hyperkalemia; monitor ECG with infusion rates >10 mEq/h. Must be diluted in appropriate IV fluids; never give undiluted due to risk of cardiac arrest. Contraindicated in severe hyperkalemia (K+ >5.5 mEq/L) and advanced renal failure.
Take this medication with food and a full glass of water to minimize gastrointestinal irritation.Swallow the tablet whole; do not crush, chew, or break it.If you have difficulty swallowing, tell your doctor; the tablet may cause esophageal ulceration.Do not take potassium supplements or salt substitutes without consulting your doctor.Seek immediate medical attention if you experience symptoms of hyperkalemia: muscle weakness, irregular heartbeat, or tingling in hands/feet.
Take potassium supplements exactly as prescribed; never double a missed dose.Avoid salt substitutes containing potassium without consulting your doctor.Report symptoms of hyperkalemia: muscle weakness, fatigue, irregular heartbeat, or tingling in hands/feet.Inform all healthcare providers that you are taking potassium supplements.Do not crush or chew extended-release tablets; swallow whole.